Rotenone (Synonyms: Nicouline, NSC 8505, NSC 26258, Tubatoxin) |
カタログ番号GC16775
One-Click Copy Product Info
|
ロテノン（Rotenone）はミトコンドリア電子伝達複合体I阻害剤であり、ミトコンドリア反応性酸素種の生産を促進することで、アポトーシスを誘発することができる。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 83-79-4
Sample solution is provided at 25 µL, 10mM.
ロテノン（Rotenone）はミトコンドリア電子伝達複合体I阻害剤であり、ミトコンドリア反応性酸素種の生産を促進することで、アポトーシスを誘発することができる。
ロテノン（1μm；36時間）でHL-60細胞を処理した。約50%のHL-60細胞は共焦点顕微鏡で、クロマチンの凝縮と核の断片化を示した[1]。ロテノン(1μM/10 nM/100 nM；24-48時間)はSK-N-MC神経芽細胞腫で用量依存的な細胞の死亡を引き起こした[3]。
ロテノン(2.5 mg/kg/日)を四週間処理した結果、SNpcのチロシン水酸化酵素（TH）陽性ドーパミン神経細胞の数を減らし、線条体のTHのシグナル強度をも減らした[2]。腎虚血再灌流モデルでは、ロテノン(200ppm；三週間)は腎尿細管を保護し、腎線維症をブロックし、炎症とアポトーシスを減少し、ミトコンドリア異常を改善する[4]。
References:
[1]. Li N, Ragheb K, Lawler G, Sturgis J, Rajwa B, Melendez JA, Robinson JP. Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production. J Biol Chem. 2003 Mar 7;278(10):8516-25.
[2]. Miyazaki I, Isooka N, Imafuku F, Sun J, Kikuoka R, Furukawa C, Asanuma M. Chronic Systemic Exposure to Low-Dose Rotenone Induced Central and Peripheral Neuropathology and Motor Deficits in Mice: Reproducible Animal Model of Parkinson's Disease. Int J Mol Sci. 2020 May 4;21(9):3254.
[3] Sherer TB, Betarbet R, Testa CM, Seo BB, Richardson JR, Kim JH, Miller GW, Yagi T, Matsuno-Yagi A, Greenamyre JT. Mechanism of toxicity in rotenone models of Parkinson's disease. J Neurosci. 2003 Nov 26;23(34):10756-64.
[4] Zhang W, Sha Y, Wei K, Wu C, Ding D, Yang Y, Zhu C, Zhang Y, Ding G, Zhang A, Jia Z, Huang S. Rotenone ameliorates chronic renal injury caused by acute ischemia/reperfusion. Oncotarget. 2018 May 11;9(36):24199-24208.
| 細胞実験[1]: | |
細胞株 | HL-60細胞 |
準備方法 | ロテノン(1μM)で36時間HL-60細胞を処理した。 |
反応条件 | ロテノン：1μM；36時間 |
アプリケーション | ロテノン（1μm；36時間）でHL-60細胞を処理した。約50%のHL-60細胞は共焦点顕微鏡で、クロマチンの凝縮と核の断片化を示した。 |
| 動物実験 [2]: | |
動物モデル | Pakanmori(PD)モデル |
準備方法 | 浸透圧ミニポンプを使って、ロテノン（2.5 mg/kg/日）を雄C57BL/6Jマウスに皮下注射した。 |
投与形態 | ロテノン（2.5 mg/kg/日）；四週間；皮下注射 |
アプリケーション | 四週間低い用量のロテノン(2.5 mg/kg/日)で慢性的な皮下投与を行った結果、SNpcのチロシン水酸化酵素（TH）陽性ドーパミン神経細胞の数を減らし、線条体のTHのシグナル強度をも減らした。 |
References: | |
| Cas No. | 83-79-4 | SDF | |
| 同義語 | Nicouline, NSC 8505, NSC 26258, Tubatoxin | ||
| Chemical Name | (2R,6aR,12aS)-8,9-dimethoxy-2-(prop-1-en-2-yl)-1,2,12,12a-tetrahydrochromeno[3,4-b]furo[2,3-h]chromen-6(6aH)-one | ||
| Canonical SMILES | O=C1[C@H](C2=CC(OC)=C3OC)[C@@H](COC2=C3)OC4=C1C=CC5=C4C[C@H](C(C)=C)O5 | ||
| Formula | C23H22O6 | M.Wt | 394.42 |
| 溶解度 | ≥ 77.6mg/mL in DMSO | Storage | Store at 4°C, stored under nitrogen |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5354 mL | 12.6768 mL | 25.3537 mL |
| 5 mM | 507.1 μL | 2.5354 mL | 5.0707 mL |
| 10 mM | 253.5 μL | 1.2677 mL | 2.5354 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 38 reference(s) in Google Scholar.)